The largest database of trusted experimental protocols

Neo hts

Manufactured by Agilent Technologies
Sourced in United States

The NEO HTS is a high-throughput screening instrument developed by Agilent Technologies. It is designed to perform automated, sensitive, and reliable analysis of small molecule samples. The NEO HTS utilizes advanced optical and fluidic technologies to enable efficient screening of large compound libraries.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using neo hts

1

SHERLOCK Assay for Malaria Detection

Check if the same lab product or an alternative is used in the 5 most similar protocols
For demonstration of specificity on clinical samples (P. falciparum n = 4 serum, n = 1 whole blood; P. vivax n = 10), 12.5 µL of serum (or whole blood) was diluted into 37.5 µL S-PREP buffer (20% [wt/vol] Chelex-100 in TE buffer with 50 mM DTT). For determination of analytical specificity, three replicates of P. falciparum, P. vivax, P. ovale, and P. malariae simulated whole-blood samples were prepared to a final concentration of 10 fM (6,020 parasites per microliter) as described above and similarly diluted in S-PREP buffer. Prepared simulated or real patient samples were then incubated at 95 °C for 10 min and transferred to a SHERLOCK lyophilized pellet, as described above, for resuspension of reaction. Fluorescence was measured over 1 h at 40 °C using a BioTek NEO HTS plate reader with readings every 3 min (excitation: 485 nm; emission: 535 nm).
+ Open protocol
+ Expand
2

Cas12a crRNA Design and Validation

Check if the same lab product or an alternative is used in the 5 most similar protocols
There are two components of Cas12a crRNAs: the universal scaffold region (UAAUUUCUA CUAAGUGUAGAU) for Cas12a protein recognition and binding and a customized region added to the 3′ end of the scaffold that provides specificity to the target sequences (the same sequence as the region following a TTTV PAM sequence). The design principle was consistent with the "CRISPR-SHERLOCK" method published by Zhang et al. 46 (link) The crRNA targeting the L108F mutation of the MPXV F8L gene was provided by Sangon Biotech (Shanghai) Co., Ltd. (see Table S1 for the crRNA sequence).
The specificity of crRNAs for different DNA templates was validated by using the CRISPR/Cas12a assay. In 10 μL volumes, 100 nM Cas12a (NEB), 100 nM crRNA, 1× NEB 2.1 buffer (NEB), 500 nM ssDNA fluorescent quenched reporter (5′ 6-FAM/TTATT/BHQ-1 3′, Sangon), and different concentrations of target dsDNA sequences diluted in RNase-free water were used. Reactions were incubated at 37 °C for 30 min, and real-time fluorescence was measured using a BioTek NEO HTS plate reader (BioTek Instruments, Winooski, VT, USA) with readings every 2 min (excitation: 485 nm; emission: 528 nm). The cis-cleavage of the sequences was further verified by electrophoresis on a 2% agarose gel at 120 V for 30 min (Figure S1).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!